USPTO serial 79223972
ONCOSIGNATURE
Reviewed by CopyMark Law Group
Reg. 5718472Status 707Registered
- Filing date
- Status date
- Registration date
- Apr 9, 2019
- Examiner
- CORWIN, CHARLOTTE K
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with ONCOSIGNATURE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Lund, SE
Watertown Massachusetts, US
Lund, SE
Lund, SE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Sara M. Bauer
Sara M. Bauer Womble Bond Dickinson (US) LLP470 Atlantic Ave; Suite 600Independence WharfBoston, MA 02210Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ Pharmaceutical preparations for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; medical preparations for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; veterinary pharmaceutical preparations for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; pharmaceutical and medical preparations for treatment, prevention and alleviation of cancer; pharmaceutical and medical preparations for the prediction of drug treatment efficacy; pharmaceutical and medical preparations for prognosis related to cancer; biological preparations for medical and veterinary purposes, namely, for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; diagnostic kits consisting primarily of monoclonal antibodies for use in disease testing, specifically in oncology and premalignant disorders and benign tumors; chemical preparations for therapeutic use, namely, for pharmaceutical or medical purposes, namely, for use in oncology, specifically the prevention, alleviation and treatment of cancer and precancerous diseases and benign tumors; reagents for medical use, namely, for medical diagnosis, drug-tailored efficacy prediction and/or analysis; clinical medical reagents; diagnostic preparations for medical and veterinary purposes; diagnostic test materials for medical use in the field of oncology in the form of a clinical biomarker signature assay on biopsy or other patient sample material for measuring biomarkers reflective of disease-driving processes that the drug inhibits and does not inhibit to predict treatment efficacy within oncology; diagnostic preparations for medical use; diagnostic biomarker reagents for medical purposes; companion diagnostic biomarker reagents for medical purposes ] | SECTION 71 - CANCELLED | — |
| 042 | [ Scientific and ] technological research and consultation services, namely, in the medical * and pharmaceutical research fields of drug-tailored, efficacy-predictive biomarkers, pharmacodynamic biomarkers, patient responder identification, and indication finding * [ pharmaceutical, and scientific research fields of drug-tailored, efficacy-predictive biomarkers, pharmacodynamic biomarkers, drug repurposing, and identification of rational drug combinations ] ; industrial analysis and research services, namely, industrial research in the field of oncology * biomarkers and predictive modeling; * basic medical research and medical clinical research, hereunder for development of therapeutics * using biomarkers and predictive modeling; * drug discovery services * in the medical and pharmaceutical research fields of drug-tailored efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers and indication finding; * consultancy in the field of pharmaceutical research and development * services in the medical and pharmaceutical research fields of drug-tailored efficacy-predictive biomarkers, patient responder identification, pharmacodynamic biomarkers and indication finding; * medical and scientific research related to cancer and cancer therapy, including research related to treatment, prevention and alleviation of cancer * in the medical and pharmaceutical research fields of drug-tailored efficacy-predictive biomarks, patient responder identification, pharmacodynamic biomarkers and indication finding; * pharmaceutical research services related to prediction of drug treatment efficacy * using biomarkers and predictive modeling; * medical research services related to cancer diagnosis, cancer prognosis and drug-tailored efficacy prediction * using biomarkers and predictive modeling; * medical research, namely, analysis related to cancer diagnosis, cancer prognosis and drug-tailored efficacy prediction * using biomarkers and predictive modeling * | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by OncoSignature AB
- Other trademarks owned by Acrivon Therapeutics Inc.
- Other trademarks owned by OncoSignature AB
- Other trademarks owned by OncoSignature AB
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ONCOSIGNATURE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 10, 2026 | INPR | PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 18, 2026 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Jul 27, 2026 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Jul 24, 2026 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jul 24, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 10, 2026 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Feb 10, 2026 | 71.P | REGISTERED - PARTIAL SEC 71 ACCEPTED | — |
| Feb 9, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 7, 2025 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Apr 18, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Mar 12, 2025 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Oct 4, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 9, 2024 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Feb 26, 2022 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jul 13, 2021 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Jul 13, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 13, 2021 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Jul 13, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 13, 2021 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Aug 16, 2019 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 31, 2019 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 31, 2019 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 9, 2019 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 9, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 25, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 25, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 25, 2019 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 22, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 22, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 9, 2019 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 9, 2019 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 2, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 17, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 13, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 13, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 13, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 13, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 27, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 3, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 3, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 2, 2018 | ALIE | ASSIGNED TO LIE | — |
| Jul 18, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 3, 2018 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 18, 2018 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 18, 2018 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 6, 2018 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 6, 2018 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 5, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 2, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 2, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 28, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |